FSIP1 and early-onset autosomal dominant Alzheimer disease: These findings suggest that inhibitor 34 has the potential to partially reverse HSD10-driven pathology in an Aβ42-rich environment and highlight it as a promising candidate for therapeutic development in Alzheimer’s disease.